Acta cardiologica · 2012
Extensive antiarrhythmic drugs after catheter ablation of persistent atrial fibrillation.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gu Jun, Liu Xu, Tan Hongwei, Zhou Li, Gu Jianing, Jiang Weifeng, Wang Yuanlong, Liu Yugang
Аннотация
OBJECTIVE: Whether early rhythm suppression with extensive antiarrhythmic drugs (AADs) in persistent atrial fibrillation (AF) after catheter ablation decreases arrhythmia recurrence is unknown. We now report the 12-month follow-up data in this prospective and randomized study.
METHODS AND RESULTS: 123 consecutive patients with persistent AF undergoing catheter ablation were randomly divided into an extensive AADs therapy group (group 1:62 patients using both class Ic and III AADs) or one AAD therapy group (group 2:61 patients using class Ic or III AADs alone) for the initial 2 months after ablation. Recurrence of atrial tachyarrhythmias (ATa) was valuated at both 2 months and 12 months following ablation. During the first 2 months after ablation, less ATa were found in group 1 compared with group 2 (17/62 versus 29/61, P = 0.021). However, there was no difference with regard to ATa at 12 months between the groups (21/62 versus 22/61, P = 0.799). ATa at 2 months and left atrial diameter (LAD) were the statistically significant predictors of ATa during 12-month follow-up.
CONCLUSIONS: While use of extensive AADs within the initial 2 months after persistent AF ablation decreases early ATa, it does not prevent late ATa. Moreover, LAD as well as early ATa is a strong predictor of ATa at 12 months.
METHODS AND RESULTS: 123 consecutive patients with persistent AF undergoing catheter ablation were randomly divided into an extensive AADs therapy group (group 1:62 patients using both class Ic and III AADs) or one AAD therapy group (group 2:61 patients using class Ic or III AADs alone) for the initial 2 months after ablation. Recurrence of atrial tachyarrhythmias (ATa) was valuated at both 2 months and 12 months following ablation. During the first 2 months after ablation, less ATa were found in group 1 compared with group 2 (17/62 versus 29/61, P = 0.021). However, there was no difference with regard to ATa at 12 months between the groups (21/62 versus 22/61, P = 0.799). ATa at 2 months and left atrial diameter (LAD) were the statistically significant predictors of ATa during 12-month follow-up.
CONCLUSIONS: While use of extensive AADs within the initial 2 months after persistent AF ablation decreases early ATa, it does not prevent late ATa. Moreover, LAD as well as early ATa is a strong predictor of ATa at 12 months.